Operations

Indegene Charts Out the Most Longitudinal Model in its Digital Maturity Study for Life Sciences Companies

February 22, 2018

PRINCETON, N.J., February 22, 2018 /PRNewswire/ —   Cross-integration of Digital Infrastructure With Hyper-segmented Channel and Content Mix to Enhance Customer Centricity   Indegene, the leading healthcare solutions provider, today unveiled its Digital Maturity Study, tracing the effectiveness of the customer engagement journey through 5 levels of channel and content maturity. The study predicts that […]

Advaxis Announces Proposed Public Offering of Common Stock

February 22, 2018

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Advaxis intends to grant the underwriters a 30-day option to purchase up to […]

Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock

February 22, 2018

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share, for gross proceeds of $176 million before deducting estimated underwriting discounts and commissions […]

Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets

February 22, 2018

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has completed the repayment in cash of the principal amount of […]

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

February 22, 2018

COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,947,368 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $57.00 per ADS. All of the ADSs […]

Adgero Biopharmaceuticals Granted FDA Orphan Drug Designation of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome

February 22, 2018

PRINCETON, NJ–(Marketwired – February 22, 2018) – Adgero Biopharmaceuticals Holdings, Inc. (“Adgero” or the “Company”), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy (“PDT”) platform for the treatment of serious cutaneous oncology indications, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to REM-001, for the treatment […]

Mount Tam Biotechnologies Announces that the European Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

February 22, 2018

NOVATO, CA , Feb. 22, 2018 (GLOBE NEWSWIRE) — Mount Tam Biotechnologies, Inc. (“Mount Tam”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce the European Patent Office has granted a key patent for its lead compound TAM-01. This patent claims TAM-01 composition of matter, […]

ContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population

February 22, 2018

EDISON, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) — ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead investigational drug candidate, tenofovir exalidex (TXL™) for the treatment of chronic hepatitis […]

Evoke Group Acquires AboveNation Media, LLC

February 22, 2018

NEW YORK, Feb. 22, 2018/PRNewswire/ — Huntsworth plc (HNT: LSE) today announces the acquisition of New York-based AboveNation Media adding to its collection of leading health, wellness and lifestyle marketing companies under Evoke Group (www.evokegroup.com). AboveNation Media, a full-service media strategy, planning and buying agency, will provide integrated advertising technology solutions across all Evoke Group […]

Pfizer’s John Davis Named Magenta Therapeutics Chief Medical Officer

February 22, 2018

Magenta Therapeutics has recruited Pfizer (NYSE: PFE) executive John Davis to serve as the startup’s new chief medical officer. Before coming to Cambridge, MA-based Magenta, Davis was Pfizer’s senior vice president and head of early clinical development. His experience also includes positions at Baxalta and Genentech. Magenta is developing treatments for bone marrow transplant patients […]

Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M

February 22, 2018

Merck & Co. has agreed to acquire Sydney-based Viralytics for approximately A$502 ($394 million), the companies said today, in a deal that expands the buyer’s immuno-oncology pipeline with a mid-stage oncolytic immunotherapy that has already shown positive clinical data in combination trials. Cavatak (coxsackievirus Type A21, or CVA21), Viralytics’ lead product, is designed to preferentially […]

Roche To Buy Oncology Software Provider Flatiron Health for $1.9bn

February 22, 2018

Swiss drugmaker Roche has agreed to acquire Flatiron Health, a US-based healthcare technology and services company, for $1.9bn.   Headquartered in New York, Flatiron Health is a provider of oncology-specific electronic health record (EHR) software.   The company, which was founded in 2012, is also engaged in curation and development of real-world evidence for cancer […]

WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

February 22, 2018

Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA SHANGHAI, 22 Feb 2018: STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery […]

Bioclinica Delivers Individual Case Safety Report (ICSR) Processing with Quality and Consistency While Crossing One Million Case Milestone in 2017

February 22, 2018

Quality and value in Bioclinica ICSR outsourcing enable drug safety operations to meet global regulatory requirements for safety monitoring of medicines PRINCETON, NJ– Bioclinica®, the world-leading provider of scientific- and technology-enabled solutions for clinical research, today announces its ICSR team delivered quality and consistency in Individual Case Safety Report (ICSR) processing while crossing the one […]

Iterum Announces the appointment of Jeff Schaffnit as Chief Commercial Officer

February 21, 2018

DUBLIN and CHICAGO, Feb. 20, 2018 /PRNewswire/ — Iterum Therapeutics Limited, a clinical-stage pharmaceutical company developing anti-infectives for patients with infectious diseases and other acute illnesses, today announced the appointment of Jeff Schaffnit as Chief Commercial Officer.   In this newly created role, which reports directly to Iterum’s Chief Executive Officer, Corey N. Fishman, Mr. […]

Rubius Therapeutics Appoints Spencer Fisk as Senior Vice President of Manufacturing

February 21, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, today announced the appointment of Spencer Fisk as Senior Vice President, Manufacturing. Mr. Fisk brings to Rubius nearly thirty years of pharmaceutical and biotechnology experience. Mr. Fisk joins Rubius from Novartis, where he […]

Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock

February 21, 2018

DURHAM, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in […]

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

February 21, 2018

COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis […]

AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations

February 21, 2018

NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced the appointment of two new executive team members. Mark Rimkus joins AIT as Vice President of Clinical Affairs […]

FEEDBACK